

AMENDMENTS TO THE CLAIMS

The claims in this listing will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Previously Presented) Use of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), the protected forms, salts and/or prodrugs thereof for producing a drug to increase the apoptotic effect of cytostatics after chemotherapy, without an additional administration of cytostatics.


2. (Previously Presented) Use according to claim 1, characterized in that at least one cytostatic in conjunction with BVDU, the protected forms, salts and/or prodrugs thereof is used during chemotherapy.

3. (Previously Presented) Use according to claim 2, characterized in that, during chemotherapy, doses of the cytostatic increasing over a defined period in combination with a constant dose of BVDU, the protected forms, salts and/or prodrugs thereof are used and subsequent to the chemotherapy, i.e. in a recovery phase, the BVDU, the protected forms, salts and/or prodrugs thereof alone are used.

4. (Previously Presented) Use according to claim 3, characterized in that the duration of the recovery phase is from 3 to 10 days.

5. (Currently Amended) Use according to ~~one of the claim 3 or 4~~ claim 3, characterized in that the duration of the chemotherapy cycle is from 8 to 30 days.

6. (Previously Presented) Use according to claim 1, characterized in that a compound of the general formula I



is used as prodrug.

7. (Currently Amended) Use according to ~~at least one of claims 1 to 6~~ claim 1, characterized in that BVDU, the protected forms, salts and/or prodrugs thereof used in a dosage which makes possible a blood concentration between 0,02 and 50 µg/ml.